Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Head and neck squamous cell carcinoma (HNSCC) exhibits CDK4/6 hyperactivation, yet response to anti-CDK4/6 therapy is often limited.
• CDK4 and CDK6 overexpression is associated with poor prognosis in HNSCC patients.

Purpose of the Study:

• To investigate the mechanisms of resistance to CDK4/6 inhibitors in HNSCC.
• To identify novel therapeutic strategies to overcome resistance and improve treatment outcomes.

Main Methods:

• Analysis of CDK4/6 and STAT3 signaling pathways in HNSCC cell lines and patient samples.
• In vitro and in vivo studies evaluating the efficacy of combined Stattic and CDK4/6 inhibitor treatment.
• Correlation analysis between phospho-STAT3 levels, RB expression, and patient prognosis.

Main Results:

• CDK4/6 inhibition activates STAT3 signaling in RB-positive HNSCC, leading to MYC upregulation and RB deficiency.
• Combined Stattic and CDK4/6 inhibitor treatment demonstrated significant anti-tumor effects in vitro and in animal models.
• Elevated phospho-STAT3 levels correlate with reduced RB expression and predict a poor prognosis in HNSCC patients.

Conclusions:

• STAT3 signaling plays a critical role in conferring resistance to CDK4/6 inhibitors in HNSCC.
• Combination therapy targeting both CDK4/6 and STAT3 pathways presents a promising strategy for HNSCC treatment.
• Phospho-STAT3 can serve as a predictive biomarker for treatment response in HNSCC.